-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2023-506675-96-00
5
2025-01-23
Heart Failure
-
2024-514656-32-00
4
2025-01-23
Suspected or confirmed Gram negative infections
-
2023-503675-24-00
5
2025-01-17
Triple-negative Breast Cancer
-
2024-511179-13-00
5
2025-01-13
Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
-
2024-516841-38-00
4
2025-01-09
recurrent ovarian cancer wild type for germline and somatic BRCA 1 and
-
2024-516842-21-00
5
2025-01-09
Recurrent ovarian cancer
-
2024-519481-44-00
4
2025-01-08
colorectal metastatic cancer
-
2023-510109-16-00
4
2025-01-06
Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
-
2024-516450-21-00
6
2024-12-31
metastatic or locally advanced urothelial cancer
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2022-501547-33-01
11
2024-12-24
Acute myocarditis
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t
-
2024-513592-41-00
6
2024-12-19
Elderly patients with a positive history of at least two respiratory s
-
2023-507332-20-00
9
2024-12-18
Dupuytren contracture
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2023-506028-10-00
7
2024-12-11
Myotonic Dystrophy
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2024-513860-25-00
9
2024-12-10
Ovarian Neoplasms
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2024-518092-62-00
5
2024-12-09
Adult critically ill patients requiring non-invasive (NIMV) or invasiv
-
2024-512053-24-00
4
2024-12-05
recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSC
-
2023-504713-76-00
5
2024-12-03
Dermatitis atopic